<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640625</url>
  </required_header>
  <id_info>
    <org_study_id>REK 2015/2125</org_study_id>
    <nct_id>NCT02640625</nct_id>
  </id_info>
  <brief_title>Improving Prognosis in HIV Infection</brief_title>
  <official_title>Adjuvant Mucosal Therapy in HIV-infected Men With Insufficient Response to Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety of probiotics in cART-treated
      immunologic non-responder (INR) patients with chronic HIV infection.

      The secondary objectives are to i) explore the biological effects of probiotics in combined
      antiretroviral therapy(cART)-treated INR patient with chronic HIV infection, and ii)
      investigate differences between cART-treated HIV-infected INR and non-INR patients with
      regards to gut microbial composition and mucosal barrier function.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>10 weeks</time_frame>
    <description>Unit of Measure:Frequency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delta HIV viral load</measure>
    <time_frame>8 weeks</time_frame>
    <description>Unit og Measure: copies/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delta blood CD4 count</measure>
    <time_frame>8 weeks</time_frame>
    <description>Unit of Measure: cells/microL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alteration in gut microbiota composition</measure>
    <time_frame>8 weeks</time_frame>
    <description>Explorative (Unit of Measure: Descriptive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in epithelial gene expression</measure>
    <time_frame>8 weeks</time_frame>
    <description>Explorative (Unit of Measure: Descriptive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in lamina propria T cell subsets</measure>
    <time_frame>8 weeks</time_frame>
    <description>Explorative (Unit of Measure: Frequency)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in systemic T cell intracellular signaling</measure>
    <time_frame>8 weeks</time_frame>
    <description>Explorative (Unit of Measure: Frequency)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in systemic markers of immune activation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Explorative (Unit of Measure: Descriptive)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Probiotic compound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic compound</intervention_name>
    <description>Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.</description>
    <arm_group_label>Probiotic compound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV seropositive &gt;4 years.

          -  Continuous cART &gt;4 years.

          -  Plasma HIV RNA &lt;50 copies/mL &gt;3,5 years.

          -  CD4+ T cell count &lt;400 cells/µL (OR &gt;600 cells/µl) &gt;3.5 years.

          -  Caucasian

          -  Signed informed consent and expected cooperation of the patients for the treatment and
             follow up must be obtained and documented according to International Committee on
             Harmonization (ICH) Good Clinical Practice (GCP), and national/local regulations.

        Exclusion Criteria:

          -  Plasma hepatitis C (HCV) RNA positive.

          -  Serum hepatitis B surface antigen (HBsAg) positive.

          -  Comorbidity of inflammatory bowel disease, coeliac disease or malnutrition.

          -  Concomitant use of non-steroid anti-inflammatory drugs (NSAID), corticosteroids,
             disease-modifying antirheumatic drugs, or other anti-inflammatory pharmaceutical
             substances.

          -  Concomitant use of antithrombotic pharmaceutical substances

          -  Regular (weekly) use of any probiotic substance within 3 months prior to inclusion.

          -  Use of antibiotics within 3 months prior to inclusion.

          -  Deranged liver function (serum albumin &lt;25 g/L or Child-Pugh ≥10)

          -  Renal failure (estimated glomerular filtration rate (eGFR) &lt;30 ml/min)

          -  Heart failure (NYHA class II-IV)

          -  Intolerance to milk or phenylalanine

          -  Any reason why, in the opinion of the investigator, the patient should not participate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dag Henrik Reikvam, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital (Ullevaal campus)</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Dag Henrik Reikvam</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Mucosal immunology</keyword>
  <keyword>Gut biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 8, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

